Ranbaxy signs licensing pact with EPIRUS Switzerland
The pact is for a biosimilar version of Infliximab prescribed to treat rheumatoid arthritis (RA).
New Delhi, January 9, 2014: Ranbaxy Laboratories has inked a licensing pact with EPIRUS Switzerland GmbH for BOW015, a biosimilar version of Infliximab prescribed to treat rheumatoid arthritis (RA). It is important to note that EPIRUS Switzerland GmbH is a wholly-owned subsidiary of Boston-based Epirus Biopharmaceuticals Inc.
The product will be introduced in India and other emerging markets and there is no biosimilar of Infliximab approved in India, the company said in a statement.
As per the terms of the agreement, EPIRUS will develop and supply the product and post securing the required approvals, Ranbaxy will market the same in India and other emerging markets.